NCT06712108 Double Unit Cord Blood Transplant in Hematologic Malignancies.
| NCT ID | NCT06712108 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Adult Double Unit Cord Blood Transplant |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-12-21 |
| Primary Completion | 2030-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-12-21 with a primary completion date of 2030-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation are evaluated through prospective observation and analysis of actual clinical data collection
Eligibility Criteria
Inclusion Criteria: * Aged 19 and older * Patients scheduled for umbilical cord blood transplantation as a primary allogeneic hematopoietic stem cell transplantation for the treatment of the following hematologic diseases: Acute leukemia (myeloid/lymphoid/mixed lineage) / Myelodysplastic syndromes / Chronic leukemia (myeloid/lymphoid/monocytic) and myeloproliferative neoplasms / Malignant lymphomas, multiple myeloma / Other malignant hematologic malignancies / bone marrow failure diseases, including aplastic anemia \- If all contents of the consent form are understood and consented to in writing. Exclusion Criteria: * Patients with a history of allogeneic hematopoietic stem cell transplantation or those undergoing transplantation for the treatment of engraftment failure (secondary allogeneic hematopoietic stem cell transplantation is an exclusion criterion; however, patients eligible for registration include those undergoing their first allogeneic stem cell transplantation following an autologous stem cell transplantation). * Patients with severe, uncontrolled infections or severe cardiopulmonary dysfunction, as judged by the investigator. * Patients with an ECOG Performance Status (PS) greater than 3 or those receiving mechanical ventilation in the intensive care unit. * Patients who do not consent to participate in the study or those deemed unsuitable for sincere participation by the attending physician.
Contact & Investigator
Dong-Yeop Shin, MD, PhD.
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT06712108 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Adult Double Unit Cord Blood Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06712108 currently recruiting?
Yes, NCT06712108 is actively recruiting participants. Contact the research team at shindongyeop@snu.ac.kr for enrollment information.
Where is the NCT06712108 trial being conducted?
This trial is being conducted at Jeonju, South Korea, Daegu, South Korea, Pusan, South Korea, Pusan, South Korea and 2 additional locations.
Who is sponsoring the NCT06712108 clinical trial?
NCT06712108 is sponsored by Seoul National University Hospital. The principal investigator is Dong-Yeop Shin, MD, PhD. at Seoul National University Hospital. The trial plans to enroll 40 participants.